Revenue Performance - Oncology services revenue for the three months ended October 31, 2022, was $14.3 million, a 21.2% increase from $11.8 million in the same period of 2021 [106]. - For the six months ended October 31, 2022, oncology services revenue reached $28.0 million, up 21.6% from $23.0 million in 2021 [106]. - Net cash provided by operating activities was $3.1 million for the six months ended October 31, 2022, compared to $1.4 million in 2021 [112]. Cost and Expenses - Cost of oncology services for the three months ended October 31, 2022, was $7.4 million, reflecting a 32.7% increase from $5.6 million in 2021 [107]. - Research and development expenses for the three months ended October 31, 2022, were $2.6 million, a 13.3% increase from $2.3 million in 2021 [109]. - General and administrative expenses for the three months ended October 31, 2022, were $2.5 million, an increase of 27.9% from $2.0 million in 2021 [111]. Financial Position - The company had an accumulated deficit of approximately $72.3 million as of October 31, 2022 [102]. - As of October 31, 2022, the company had cash of $10.8 million and working capital of $1.9 million [102]. - The company has no off-balance sheet debt or similar obligations, ensuring transparency in financial reporting [118]. Strategic Initiatives - The company plans to implement cost reduction strategies if revenue expectations do not materialize [102]. - The company launched Lumin Bioinformatics, an oncology data-driven software program, as part of its growth strategy [98]. Accounting and Estimates - Significant estimates affecting financial statements include accounts receivable realization and revenue recognition [115]. - The company's critical accounting policies are detailed in the Annual Report on Form 10-K filed on July 22, 2022 [115].

Revenue and Expenses - Oncology services revenue for the three months ended July 31, 2022, was $13.7 million, an increase of 22.1% from $11.3 million in the same period of 2021 [102]. - Cost of oncology services increased to $7.1 million for the three months ended July 31, 2022, representing a 30.7% rise from $5.4 million in 2021 [103]. - Research and development expenses rose to $2.9 million for the three months ended July 31, 2022, a 25.3% increase from $2.3 million in 2021 [106]. - Sales and marketing expenses increased to $1.7 million for the three months ended July 31, 2022, up 7.5% from $1.6 million in 2021 [107]. - General and administrative expenses were $2.4 million for the three months ended July 31, 2022, an increase of 11.3% from $2.2 million in 2021 [108]. Net Loss and Financial Position - The company reported a net loss of approximately $319,000 for the three months ended July 31, 2022, compared to a net loss of $175,000 in the same period of 2021 [100]. - As of July 31, 2022, the company had an accumulated deficit of approximately $72.3 million and cash of $8.1 million [100]. - The company believes its cash on hand, along with expected positive cash flows for fiscal year 2023, are adequate to fund operations for at least 12 months [100]. Strategic Initiatives - The company launched Lumin Bioinformatics, a new oncology data-driven software program, during fiscal 2021 to enhance drug discovery [95]. - The company is exploring strategic options, including potential spin-out transactions or capital raises, to create additional value from its drug discovery business [99].

Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen, and welcome to the First Quarter Fiscal Year 2023 Champions Oncology Conference Call [Operator Instructions]. It is now my pleasure to turn the floor over to your host, Ronnie Morris, CEO of Champions Oncology. Sir, the floor is yours. Ron ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |------------------------------------------------------------------------------------------ ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2022 Earnings Conference Call March 15, 2022 4:30 PM ET Company Participants Ronnie Morris – Chief Executive Officer David Miller – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Operator Good afternoon, ladies and gentlemen, and welcome to the Champions Oncology Third Quarter Fiscal Year 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode. And we will open the floor for your questi ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

Revenue Performance - Oncology services revenue for the three months ended October 31, 2021, was $11.8 million, a 16.5% increase from $10.1 million in the same period of 2020[111] - For the six months ended October 31, 2021, oncology services revenue reached $23.0 million, up 17.2% from $19.7 million in the prior year[111] Gross Margins - Gross margins for oncology services improved to 52.4% for the three months ended October 31, 2021, compared to 44.2% in the same period of 2020[112] Expenses - Research and development expenses increased by 39.3% to $2.3 million for the three months ended October 31, 2021, from $1.7 million in 2020[113] - Sales and marketing expenses rose by 21.7% to $1.6 million for the three months ended October 31, 2021, compared to $1.3 million in the same period of 2020[114] - General and administrative expenses increased by 34.5% to $2.0 million for the three months ended October 31, 2021, from $1.5 million in 2020[115] - Total costs and operating expenses for the six months ended October 31, 2021, were $22.9 million, a 16.9% increase from $19.6 million in 2020[110] Cash Flow and Financial Position - Net cash provided by operating activities was $1.4 million for the six months ended October 31, 2021, compared to $164,000 in the same period of 2020[118] - The company had an accumulated deficit of approximately $72.4 million as of October 31, 2021[107] - Cash on hand as of October 31, 2021, was $4.8 million, with working capital of $1.2 million[107]

Financial Data and Key Metrics Changes - The first quarter revenue reached a record $11.3 million, an increase of $1.7 million or 18% compared to $9.5 million in the same period last year [11] - Gross margin improved to 53% from 44% year-over-year, despite total cost of sales remaining flat at $5.3 million [12][13] - Cash-based expenses increased to $10.8 million from $9.1 million, primarily due to increased R&D investment and salesforce expansion [16] Business Line Data and Key Metrics Changes - The oncology research services business continued to expand and produce positive financial results, contributing to overall revenue growth [10] - R&D expenses rose to approximately $2.3 million, a 44% increase from $1.6 million, reflecting a strategic focus on long-term growth [14] - Sales and marketing expenses increased by 31% to $1.5 million, driven by compensation-related expenses from an expanded sales team [15] Market Data and Key Metrics Changes - The company has sold licenses to over 100 unique customers for its new software platform Lumin, indicating strong market interest [7] - The European lab is operational, with expectations to begin signing contracts by the end of the year, enhancing the company's international capabilities [25][28] Company Strategy and Development Direction - The company is focused on leveraging its unique PDX tumor bank and scientific platform to enhance its oncology research services and software offerings [6] - A new software platform, Lumin, has been launched, aimed at providing advanced data interpretation capabilities, with ongoing development based on customer feedback [7] - The company is advancing therapeutic targets through its internal computational discovery team, validating more than six targets for further development [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robustness of budgets and pipelines, particularly in the preclinical space, despite some delays in decision-making due to the pandemic [32] - The company anticipates continued growth in its biomarker business, particularly with the opening of the European lab, which is expected to facilitate larger studies [27][28] - Management is optimistic about the future, highlighting the strength of the oncology services business and the potential of the software services and therapeutic discovery initiatives [35] Other Important Information - The company reported no debt and had $4 million in cash at the end of the first fiscal quarter [17] - Net cash generated from operating activities was $216,000, while cash used in investing activities was primarily for software platform development and laboratory expansions [17] Q&A Session Summary Question: Feedback on customer renewals and expansions - Management noted that renewal rates were over 80% for a small number of contracts, emphasizing the importance of user comfort with the platform [22] Question: Update on the services component of the Lumin platform - The services component has launched and is seeing traction, expected to be a significant revenue driver as customers engage more deeply with the platform [24] Question: Status of the European lab and contract signing - The European lab is operational, with compliance certification in progress, and management expects to begin serious proposals by the end of the year [25] Question: Progress of the flow cytometry business - The biomarker business is growing steadily, with the European site expected to enhance capabilities for larger studies [27][28] Question: Impact of pandemic on business operations - The company has not seen significant fluctuations in preclinical business, with robust budgets and strong customer return rates [32]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|-------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |------------------------------------------------------------------------------------------ ...